Table 2.
Univariate analysis of different prognostic factors in 246 HCC patients
|
Variable |
Overall survival rate (%) |
Disease-free survival rate (%) |
||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Age (years) |
1.037(0.674-1.596) |
0.867 |
1.120(0.816-1.539) |
0.482 |
| Gender |
0.74(0.356-1.536) |
0.419 |
1.215(0.741-1.990) |
0.44 |
| HBsAg |
0.776(0.421-1.431) |
0.416 |
1.140(0.697-1.865) |
0.601 |
| AFP (ng/ml) |
3.408(2.038-5.698) |
< 0.001 |
2.088(1.499-2.909) |
< 0.001 |
| Liver cirrhosis |
1.087(0.672-1.760) |
0.733 |
1.174(0.813-1.694) |
0.392 |
| Tumor size (cm) |
2.409(1.532-3.790) |
< 10.001 |
1.806(1.311-2.488) |
< 0.001 |
| Tumor multiplicity |
3.233(2.022-5.168) |
< 0.001 |
1.972(1.429-2.722) |
< 0.001 |
| Tumor differentiation |
1.649(1.246-2.183) |
< 0.001 |
1.621(1.314-2.000) |
< 0.001 |
| Clinical stage |
3.079(2.269-4.178) |
< 0.001 |
1.785(1.457-2.187) |
< 0.001 |
| Vascular invasion |
4.704(3.027-7.311) |
< 0.001 |
2.393(1.714-3.341) |
< 0.001 |
| AZGP1 | 0.553(0.359-0.851) | 0.007 | 0.706(0.513-0.972) | 0.033 |
CI, confidence interval; HR, hazard ratio; AFP, alpha-fetoprotein; HBsAg, hepatitis B surface antigen; AZGP1, zinc-alpha2-glycoprotein.